<DOC>
	<DOCNO>NCT01273571</DOCNO>
	<brief_summary>The purpose study investigate potential interaction multiple oral dos canagliflozin single oral dose metformin healthy adult volunteer .</brief_summary>
	<brief_title>A Pharmacokinetic Pharmacodynamic Study Metformin Canagliflozin Healthy Adult Volunteers</brief_title>
	<detailed_description>This open-label ( volunteer know name treatment assign ) single-center study canagliflozin metformin healthy adult volunteer . Canagliflozin ( Sodium-Glucose Cotransporter 2 inhibitor ) currently development low blood sugar level patient type 2 diabetes mellitus ( T2DM ) metformin approved treatment patient T2DM . Canagliflozin administer orally ( mouth ) single 300-mg tablet Days 4 , 5 , 6 , 7 , 8 metformin administer orally two 1,000 mg tablet Days 1 8 . Both canagliflozin metformin tablet take 8 ounce ( 240 mL ) water .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Canagliflozin</mesh_term>
	<criteria>Healthy volunteer body mass index ( BMI , measure person 's weight relation height ) 18 30 kg/m2 , inclusive . History current clinically significant medical illness determine Investigator History clinically significant allergy , especially know hypersensitivity intolerance lactose Known allergy canagliflozin metformin excipients formulation canagliflozin metformin Known allergy heparin history heparin induce thrombocytopenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Canagliflozin</keyword>
	<keyword>Metformin ( GLUCOPHAGE IR )</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>